Financial Contrast: Amphastar Pharmaceuticals (AMPH) versus Teligent (TLGT)

Amphastar Pharmaceuticals (NASDAQ: AMPH) and Teligent (NASDAQ:TLGT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Earnings and Valuation

This table compares Amphastar Pharmaceuticals and Teligent’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amphastar Pharmaceuticals $255.16 million 3.48 $10.53 million N/A N/A
Teligent $66.88 million 3.13 -$11.98 million ($0.23) -17.04

Amphastar Pharmaceuticals has higher revenue and earnings than Teligent.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Teligent has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Profitability

This table compares Amphastar Pharmaceuticals and Teligent’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amphastar Pharmaceuticals 0.12% 2.30% 1.74%
Teligent -16.95% -6.51% -1.92%

Insider & Institutional Ownership

44.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.8% of Teligent shares are owned by institutional investors. 11.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 22.6% of Teligent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Amphastar Pharmaceuticals and Teligent, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amphastar Pharmaceuticals 0 2 4 0 2.67
Teligent 0 2 1 0 2.33

Amphastar Pharmaceuticals currently has a consensus target price of $20.83, suggesting a potential upside of 7.94%. Teligent has a consensus target price of $7.00, suggesting a potential upside of 78.57%. Given Teligent’s higher possible upside, analysts clearly believe Teligent is more favorable than Amphastar Pharmaceuticals.

Summary

Amphastar Pharmaceuticals beats Teligent on 9 of the 12 factors compared between the two stocks.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

About Teligent

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply